SCHEMBL19259421

SCHEMBL19259421

Clc1cc(Cl)nc(-c2ccccc2Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.62
HSP90AB1 P08238 2/20 0.62
IDO1 P14902 1/20 0.48
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
ALPL P05186 1/20 0.44
DCUN1D1 Q96GG9 2/20 0.43
LDHA P00338 1/20 0.43
MAOB P27338 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
CCR1 P32246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30198849 1.00 HSP90AA1 (0.62) HSP90AA1HSP90AB1IDO1ADORA2AADORA1
SCHEMBL19272622 0.81 HSP90AA1 (0.50) HSP90AA1HSP90AB1IDO1ADORA2AADORA1
SCHEMBL12303170 0.81 HSP90AA1 (0.59) HSP90AA1HSP90AB1IDO1MAOBKDM5B
SCHEMBL3327517 0.80 HSP90AA1 (0.68) HSP90AA1HSP90AB1IDO1ADORA2AADORA1
SCHEMBL3950560 0.77 HSP90AA1 (1.00) HSP90AA1HSP90AB1ADORA2AADORA1KDM4E
SCHEMBL6586882 0.77 HSP90AA1 (0.64) HSP90AA1HSP90AB1IDO1ADORA2AADORA1
SCHEMBL20764969 0.77 HSD11B1 (0.47) CYP1A2CYP3A4CYP2D6TSHRCYP2C19
SCHEMBL30514768 0.77 HSD11B1 (0.47) CYP1A2CYP3A4CYP2D6TSHRCYP2C19
SCHEMBL969554 0.77 HSP90AA1 (0.54) HSP90AA1HSP90AB1IDO1KDM5BMAPT
SCHEMBL38655879 0.76 HSP90AA1 (0.62) HSP90AA1HSP90AB1ADORA2AADORA1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Spring Bioscience AB (SE) 2024-02-15 US disclosed
CN-116903526-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-20 CN disclosed
CN-116891431-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-17 CN disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
CN-116589461-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
CN-116589462-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
EP-3672948-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS Sprint Bioscience AB (SE) 2020-07-01 EP disclosed
EP-3416945-B1 6-ARYL-4-(MORPHOLIN-4-YL)-1H-PYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2020-07-01 EP disclosed
CN-111247144-A Azaindolylpyridinone compounds and diazaindolylpyridinone compounds 思普瑞特生物科学公司 2020-06-05 CN disclosed
CN-111094244-A Pyridylpyridone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
CN-111094271-A Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
WO-2019038389-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038384-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
EP-3416945-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Sprint Bioscience AB (SE) 2018-12-26 EP disclosed
WO-2017140841-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS AZI2, IAPP, ZFX HSP90AA1 4602/4885HSP90AB1 4657/4885IDO1 185/4885
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds PDXK, PLPBP, PNPO HSP90AA1 4812/4885HSP90AB1 4764/4885IDO1 20/4885
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES PYCR1, GPR119, CDK6 HSP90AA1 3535/4885HSP90AB1 3850/4885IDO1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.